NCT00116012View on ClinicalTrials.gov

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2005

Conditions
Coronary Disease
Interventions
DRUG

rNAPc2

Trial Locations (1)

Unknown

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

The TIMI Study Group

OTHER

lead

ARCA Biopharma, Inc.

INDUSTRY